Viewing StudyNCT02421939



Ignite Creation Date: 2024-05-06 @ 3:59 AM
Last Modification Date: 2024-10-26 @ 11:41 AM
Study NCT ID: NCT02421939
Status: ACTIVE_NOT_RECRUITING
Last Update Posted: 2024-06-24
First Post: 2015-04-16

Brief Title: A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia AML With FMS-like Tyrosine Kinase FLT3 Mutation
Sponsor: Astellas Pharma Global Development Inc
Organization: Astellas Pharma Inc

Conditions & Keywords Data

Conditions:
Name
Leukemia Acute Myeloid AML
Keywords:
Name View
XOSPATA View
ASP2215 View
Relapsed Acute Myeloid Leukemia View
FLT3 Mutation View
gilteritinib View
Refractory Acute Myeloid Leukemia View
Acute Myeloid Leukemia AML View